Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples

Szu-Ying Chen, Martin Cienciala, Tasfia Rashid, Bonell Patino Escobar, Laura Berne, Daniel Georgiev, Arun P Wiita

Blood (2024) 144 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2024-208091

Published: 2024

Journal Articles

HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies

Hiroyuki Takamatsu, Emilio Ramos, Bonell Patino-Escobar, Corynn Kasap, Adila Izgutdina, Juwita Werner, Akihito Inagaki, Takeshi Yoroidaka, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, Elliot Stieglitz, Masaki Nagato, Satoshi Tatsuno, Arun P Wiita

Blood (2024) 144 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2024-193709

Published: 2024

Journal Articles

Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia

Amrik S Kang, Haley Johnson, Nabeel Razi, Nicole Lei, Aaron C. Logan, Benjamin J Huang, Arun P Wiita

Blood (2024) 144 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2024-206484

Published: 2024

Journal Articles

Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma

Nikhil Chilakapati, Bonell Patino-Escobar, Jonathan deMontagnac, Haley Johnson, Emilio Ramos, Paul Phojanakong, Fernando Salangsang, Veronica Steri, William J Karlon, Arun P Wiita

Blood (2024) 144 (Supplement 1): 2036.

https://doi.org/10.1182/blood-2024-206274

Published: 2024

Journal Articles

CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?

Bonell Patiño-Escobar, Lucy Perez-Lugo, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, Oscar A Aguilar, Arun P Wiita

Blood (2024) 144 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2024-206465

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Blood (2023) 142 (Supplement 1): 465.

https://doi.org/10.1182/blood-2023-182578

Published: 2023

Journal Articles

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Adila Izgutdina, William C Temple, Matthew Andrew Nix, Huimin Geng, Emilio Ramos, Akul Naik, Rebecca Larson, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Ons Zakraoui, Isa Tariq, Marcela V Maus, Veronica Steri, Arun P Wiita

Blood (2023) 142 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2023-182873

Published: 2023

Journal Articles

Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

William C Temple, Gianina Wicaksono, Akul Naik, Adila Izgutdina, Matthew A Nix, Elizabeth Young, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, Fernando Salangsang, Arun P Wiita

Blood (2022) 140 (Supplement 1): 7394–7395.

https://doi.org/10.1182/blood-2022-168490

Published: 2022

Journal Articles

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Blood (2022) 140 (Supplement 1): 867–868.

https://doi.org/10.1182/blood-2022-162697

Published: 2022

Journal Articles

Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Alexis Talbot, Solène Weill, Eléonore Fox, Léa Meunier, Guillaume Appé, Camille Marijon, Abdelkader Behdenna, Arun P Wiita, Akpéli Nordor, Justin Eyquem

Blood (2022) 140 (Supplement 1): 7094–7095.

https://doi.org/10.1182/blood-2022-168403

Published: 2022

Journal Articles

CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies

Matthew A Nix, William C Temple, William Karlon, Donghui Wang, Paul Phojanakong, Veronica Steri, Byron Hann, Arun P Wiita

Blood (2021) 138 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2021-153935

Published: 2021

Journal Articles

Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma

Priya Choudhry, Olivia Gugliemini, Huimin Geng, Vishesh Sarin, Letitia Sarah, Yu-Hsiu T. Lin, Neha Paranjape, Poornima Ramkumar, Makeba Marcoulis, Donghui Wang, Paul Phojanakong, Veronica Steri, Byron Hann, Martin Kampmann, Arun P Wiita

Blood (2021) 138 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2021-147007

Published: 2021

Journal Articles

Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

Aditi Sharma, Abhinav Achreja, Remya Nair, Pulkit Gupta, Claudia L Edgar, Olamide Animasahun, Anjali Mittal, Bhakti Dwivedi, Manoj Bhasin, Vikas A Gupta, Benjamin G Barwick, Shannon M Matulis, Sagar Lonial, Lawrence H. Boise, David L Jaye, Arun P Wiita, Ajay K. Nooka, Deepak Nagrath, Mala Shanmugam

Blood (2021) 138 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2021-153744

Published: 2021

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

NARROW

Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples

HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies

Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia

Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma

CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models

Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies

Functional Multi-Omics Reveals Genetic and Pharmacologic Regulation of Surface CD38 in Multiple Myeloma

Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only